Résumé : On assiste au rajeunissement de l'usage du cannabis / marijuana / shit à l'accroissement du nombre de personnes qui s'y adonnent et à la diffusion de





télécharger 146.22 Kb.
titreRésumé : On assiste au rajeunissement de l'usage du cannabis / marijuana / shit à l'accroissement du nombre de personnes qui s'y adonnent et à la diffusion de
page11/11
date de publication17.09.2017
taille146.22 Kb.
typeRésumé
m.20-bal.com > Biología > Résumé
1   2   3   4   5   6   7   8   9   10   11

  • Gifford A.N., Bruneus M., Gatley S.J., Lan R., Makriyannis A., Volkow N.D. 1999. Large receptor reserve for cannabinoid actions in the central nervous system. J. Pharmacol. exp. Ther. 288 : 478 - 483

  • Glass M., Feider C.C. 1997. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons : evidence for a Gs linkage to CB1 receptor . J. Neurosci. 17 : 5327 - 5333.

  • Grant B., Pickering R. 1998. The relationship between cannabis use and DSM - IV cannabis abuse and dependence : results from the National Longitudinal Alcohol Epidemiologic Survey. J. Subst. Abuse 10 : 255 - 264.

  • Hall W., Degenhardt. 2000. Cannabis use and psychosis : a review of clinical and epidemiological evidence. Aust. NZJ. Psychiatry 34 : 26 - 34.

  • Hambrecht M., Haffner H. 2000. Cannabis, vulnerability and the onset of schizophrenia : an epidemiological perspective. Aust. N. Z. J. Psychiatry 34 : 468-475.

  • Haney M., Ward A. S., Comer S. D., Hart C.L., Foltin R. W., Fischman M.W ; 1999. Abstinence symptoms following smoked marijuana in humans. Psychopharmacol. 141 : 395 - 404.

  • Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., Foltin R.W. 2004. Marijuana withdrawal in humans : effects of oral THC or Divalproex. Neuropsychopharmacol. 29 : 158-70

  • Harder S, Rietbrock S. 1997. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int. J. Clin. Pharmacol. Ther. 35 : 155-9.

  • Herkenham, M., Lynn A.B., Little MD., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C. 1990. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87 : 1992 - 1936.

  • Heyser C.J., Hampson R.E. , Deadwyler S.A. 1993. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats : alterations in short term memory associated with changes in task. Specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264 : 294 - 307.

  • Arias Horcajadas F., Sanchez Romero S., Padin Calo J.J. 2002. Relevance of drug use in clinical manifestations of schizophrenia. Actas Esp. Psiquiatr. 30 : 65-73.

  • Howlett A.C., 1984. Inhibition of neuroblastoma adenylyl cyclase by cannabinoid and nantradol compounds. Life Sci. 35 : 1803 - 1810.

  • Huestis M.A., Sampson A.H., Holicky B.J., Henningfield J.E., Cone E.J. 1992. Characterization of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther. 52:31-41.

  • Huestis M.A., Cone E.J. 1998. Urinary excretion half-life of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans. Ther. Drug Monit. 20:576-576.

  • Hungund B.L., Szakall I., Adam A., Basavarajappa B.S., Vadasz C. 2003. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol induced dopamine release in the nucleus accumbens. J. Neurochem. 84 : 882 - 855.

  • Hutcheson D. M., Tavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., Maldonado R. 1998. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br. J. Pharmacol. 125 : 1567 - 1577.

  • Johansson E., Noren K, Sjovall J., Halldin M.M. 1989. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed. Chromatogr. 3:35-38.

  • Johns A., 2001. Psychiatric effects of Cannabis. Brit. J., Psychiatry 178 : 116 - 122.

  • Kim D., Thayer S.A. 2001. Cannabinoids inhibit the formation of synapses between hippocampal neurons in culture. J. Neurosci. 21 : 4026 - 4031.

  • Kreitzer A.C., Regehr. W.G. 2002. Retrograde signaling by endocannabinoids. Curr. Opin. Neurobiol. 12 : 324 - 330.

  • Ledent C., Valverde O., Cossu G., Pettitet F., Aubert J. F., Beslot F., Bohme G.A. Imperato A., Pedrazzini T., Roques B, Vassart G., Fratta W., Parmentier M. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knock out mice. Science 283 : 401 - 404.

  • Lepore M., Vorec S. R., Lowinson J, Gardner E. L. 1995. Conditioned place preference induced by delta-9-tetrahydrocannabinol : Comparison with cocaine, morphine and food reward. Life Sci. 56 : 2073 - 2080.

  • Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. 1999. Elevated endogenous cannabinoids in schizophrenia. Neuro Report 10 : 1665 – 1669.

  • Licanin I., Music E., Laslo E., Berg-Kelly K, Massic I., Redzic A., Vejzagic A., Krosnjar A. 2003. Suicidal thoughts related to psychoactive substance abuse among adolescents. Med. Arh. 57 : 237 - 240.

  • Lichtman A.H., Dimen D.R., Martin B.R. 1995. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacol. 119 : 282 – 290.

  • Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthur DB, Wilson DM, Martin BR. 1998. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs. Eur. J. Pharmacol. 18 : 139-48.

  • Lichtman A.H., Varvel S.A., Martin B.R., 2002. Endocannabinoids in cognition and dependence. Prostaglandins Leukot. Essent. Fatty Acids. 66 : 269 - 285.

  • Mackie K., Lay Y., Westenbroeck R., Mitchell R. 1995. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q - type calcium currents in At T20 cells transfected with rat brain cannabinoid receptor . J. Neurosci. 15 : 6552 - 6561.

  • Marchese G., Casti P., Ruiu S., Saba P., Sanna A., Casu G., Pani L. 2003. Haloperidol but not clozapine produces dramatic catalepsy in delta-9-tetrahydrocannabinol treated rats : possible clinical implications. Brit. J. Pharmacol. 140 : 520 – 526.

  • Martellota M. C., Cossu G., Fattore L., Gessa G. L. Fratta W. 1998. Self administration of the cannabinoid receptor agonist WIN 55, 212 - 2 in drug naive mice. Neuroscience 85 : 327 - 330.

  • Mascia M.S., Obinu M.C., Ledent C., Parmentier M., Böhme G.A., Imperato A., Fratta W. 1999. Lack of morphine-induced dopamine release in the nucleus accumbens for cannabinoid CB1 receptor knock-out mice. European J. Pharmacol. 383 : R1 - R2.

  • Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T. I. 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 : 561 - 564

  • Mechoulam R., Hanus C. 2002. Cannabidiol : an overview of some chemical and pharmacological aspects. Part I : Chemical aspects. Chemistry and Physics of lipids. 121 : 35-43.

  • Mechoulam R., Parker L. 2003. Cannabis and alcohol - a close friendship. TIPS. 24 (6) : 266 - 268.

  • Mishima K., Egashira N. Matsumoto Y., Iwasaki K., Fujiwara M. 2002. Involvement of reduced acetylcholine release in delta 9 tetrahydrocannabinol-induced impairment of spatial memory in the 8 – arm radiamaze. Life Sci. 2 : 397 - 407.

  • Mu J., Zhuang S.Y., Kirby M.T., Hampson R.E., Deadwyler S.A. 1999. Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J. Pharmacol. Exp. Ther 291 : 893 - 902.

  • Munro S., Thomas K.L., Abu-Shaar, M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 : 61 - 65.

  • Mura P. 2002. Accidentologie et drogues illicites. Bull. Acad. Natle Méd. 186 : 73 - 86.

  • Mura P., Kintz P., Ludes B., Gaulier J.M., Marquet P., Martin - Dupont S., Vincent F., Kaddour A., Goullé J.P., Nouveau J., Moulsma M., Thillet - Coartets S., Pourrat O. 2003. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects : results of a french collaborative study. Forensic. Sci. Int. 133: 78 - 85.

  • Navarro M., Hernandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., Rodriguez de Fonseca F. 1997. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716 A induces anxiety-like response in the rat. Neuro Report 8 : 491-496.

  • Nunez L.A., Gurpegui M. 2002. Cannabis-induced psychosis : a cross-sectional comparison with acute schizophrenia. Acta Psychiatr. Scand. 105 : 173-178.

  • Onaivi E.S., Green M.R. Martin B.R. 1990. Pharmacological characterization of cannabinoid in the elevated plus maze. J. Pharmacol. Exp. Ther. 253, 1002 - 1009.

  • Padley J.R., Li Q., Pilowsky P.M., Goodchild A.K. 2003. Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anesthetised rats. Brit. J. Pharmacol 2003, 140, 384 – 394.

  • Paris M., Tran N. 1998. The existence of "Nederwiet", a new fact in the history of cannabis. Ann. Pharm. Fr. 56 : 264 – 7.

  • Patton G., Cokfey C., Carling J.-B., Degenhardt L., Lynskey M., Hall W. 2002. Cannabis use and mental health in young people : cohort study. Brit. Med. J. 325 : 1195 - 1198.

  • Pontieri F.E., Monnazzi P., Scontrini A., Buttarelli F.R. 2001. Behavioral sensitization to heroin by cannabinoid pre-treatment in the rat. Europ. J. Pharmacol. 421 : R1-R3.

  • Pope H .G., Jacobs A., Mialet J.P., Yurgelun-Todd D., Gruber S. 1997 Evidence of a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom. 66 : 179-184.

  • Potvins S., Stip E., Roy J.-Y. 2003. Schizophrénie et addiction : évaluation de l'hypothèse d'une automédication. Encéphale. 29 : 193 - 203.

  • Prather P.L., Martin N.A., Breivogel C.S., Childers R.S. 2000. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein-subunits with different potencies. Mol. Pharmacol. 57:1000-1010.

  • Rey J., Sawyer M., Raphael B., Patton G., Lynskey M. 2002. Mental health of teenager who use cannabis. Brit. J. Psychiatry 180 : 216 - 221.

  • Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. 2001. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci. 21 : 109 – 116.

  • Rodriguez de Fonseca F., Carrera M. R. A., Navarro M., Koob G. B., Weiss F. 1997. Activation of corticotrophin releasing factor in the limbic system during cannabinoid chwartz R.H., 2002. Marijuana a decade and a half later, still a crude drug with under appreciated toxicity. Pediatrics 284 – 289. withdrawal Science 276 : 2050 - 2054.

  • Schwartz R.H., Gruenewald P.J., Klitzner M., Fedio P. 1989. Short term memory in cannabis dependent adolescents. Am. J. Dis . Child. 143 : 1214-1219

  • Serra S., ,Brunnett G., Pani M., Vacca G., Carai M.A., Gessa G.L., Colombo G. 2001. The cannabinoid receptor antagonist S R 141 716 prevents acquisition of drinking behaviour in alcohol - preferring rats. Eur. J. Pharmacol. 430 : 369 - 371.

  • Shen M., Piser T.M., Seybold V.S., Thayer S.A. 1996. Cannabinoid receptor agonist transmission in rat hippocampal culture. J. Neurosci. 16 : 4322 - 4334.

  • Smith-Kielland A., Skuterud B., Morland J. 1999. Urinary excretion of 11-NOR-9-carboxy-delta-9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J. Anal. Toxicol. 23 : 323-332.

  • Tanda G., Pontieri F.E., Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopaminergic transmission by a common 1 opioid receptor mechanism. Science 276 : 2048-2050.

  • Tanda G ., Loddo P., Di Chiara G. 1999. Dependence of mesolimbic dopamine transmission on delta-9-tetrahydrocannabinol. Eur. J. Pharmacol. 376 : 23 - 26.

  • Tournier M., Sorbara F., Gindre C, Swendsen J.D., Verdoux H., 2003. Cannabis use and anxiety in daily life : a naturalistic investigation in a non clinical population. Psychiatry Res. 118 : 1-8.

  • Tsou K., Patrick S.L., Walker J. M. 1995. Physical withdrawal in rats tolerant to delta-9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Europ. J. Pharmacol. 280 : R13 - R15.

  • Tseng A.H., Craft R.M., 2001. Sex differences in antinociceptive and motoric effects of cannabinoids. Europ. J. Pharmacol. 430 : 41 – 47.

  • Tzavara E.T., Wade M., Nomikos G.G. 2003. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci. 15 : 9374-84.

  • Vacca G., Serra S., Brunetti G., Carai M.A., Carai M.A., Gessa G.L., Colombo G. 2002. Boosting effect of morphine on alcohol drinking is suppressed not only by naloxone but also by the cannabinoid CB1 receptor antagonist SR 141716. Europ. J. Pharmacol. 445 : 55-59.

  • Valjent E., Maldonado R. 2000. A behavioral model to reveal place preference to delta-9- tetrahydrocannabinol in mice. Psychopharmacol. 147 : 436 - 438.

  • Voruganti L.N., Slomka P., Zabel P., Mattar A., Awad A.G. 2001. Cannabis –induced dopamine release : an in vivo SPECT study. Psychiat. Res. 107 : 173-177.

  • Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., Delorenzo R.J. 2003. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. exp. Ther. 307 : 129 - 137.

  • Yao L., Fan P., Jiang Z., Mailliard W.S., Gordon A.S., Diamond I. 2003. Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi- dimers. Proc. Nat. Acad. Sci. 100 : 14379 – 14384.

  • Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. 2002. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969 : Historical cohort study. Brit. Med. J. 325 : 1199 -1205.

  • Zavitsanou K., Garrick T., Huang X.F. 2004. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 28(2):355 - 60.







1   2   3   4   5   6   7   8   9   10   11

similaire:

Résumé : On assiste au rajeunissement de l\Résumé : Ce travail de recherche porte sur un médicament, le Mediator,...
«coupe faim» par des personnes non diabétiques est à l’origine d’un scandale sanitaire en raison d’effets secondaires très graves...

Résumé : On assiste au rajeunissement de l\Cannabis – le professeur Costentin répond aux déclarations du professeur Dautzenberg
«l’herbe», «la beuh» (en verlan), «la marijuana», usant alors, puis abusant bientôt des fameux «pétards». Pour ce faire, IL propose...

Résumé : On assiste au rajeunissement de l\Guide du bon usage des blogs scolaires
«service de communication au public en ligne», le site Web doit obligatoirement afficher des informations sur les personnes qui l’éditent...

Résumé : On assiste au rajeunissement de l\Résumé : Cette communication consiste en une étude des pratiques...
«media agenda setting» est également mobilisée afin de proposer une mesure de la pression du public qui sera mise en relation avec...

Résumé : On assiste au rajeunissement de l\RÉsumé. Dans le cadre de l’apprentissage collaboratif assisté par...

Résumé : On assiste au rajeunissement de l\Résumé Le secteur de la micro-finance en République Démocratique...

Résumé : On assiste au rajeunissement de l\Préparation et mode d’utilisation
«cannabis» du latin cannabus ou cannabis, directement dérivé du grec kannabis le terme grec dérive lui même de l’assyrien quanabu...

Résumé : On assiste au rajeunissement de l\Résumé L’étude retard concerne des personnes séropositives qui accèdent...

Résumé : On assiste au rajeunissement de l\«Dépil’tech» est le leader de l’épilation définitive et du rajeunissement
...

Résumé : On assiste au rajeunissement de l\«Dépil’tech» est le leader de l’épilation définitive et du rajeunissement
...





Tous droits réservés. Copyright © 2016
contacts
m.20-bal.com